AstraZeneca surges after HHS provides $500 million for Covid-19 antibody treatment development

AstraZeneca stocks are up after news that its Covid-19 antibody treatments is moving into phase 3 clinical trials and that the HHS will provide $500 million for the company to produce and manufacture these treatments. CNBC's Sara Eisen joins 'Closing Bell' to discuss.
00:24
Fri, Oct 9 20206:09 PM EDT